Smoking in pregnancy is associated with increased total maternal serum cell-free DNA levels

2008 ◽  
Vol 28 (3) ◽  
pp. 186-190 ◽  
Author(s):  
Adam C. Urato ◽  
Inga Peter ◽  
Jacob Canick ◽  
Geralyn Lambert-Messerlian ◽  
Andrea Pulkkinen ◽  
...  
Keyword(s):  
Maternal Serum ◽  
Cell Free Dna ◽  
Smoking In Pregnancy ◽  
Free Dna ◽  
In Pregnancy

scholarly journals OC21.05: Implications of inconclusive results in prenatal maternal serum cell-free DNA testing

2017 ◽  
Vol 50 ◽  
pp. 44-44
Author(s):  
M. Smet ◽  
N. Chan ◽  
A. McLennan ◽  
F. da Silva Costa
Keyword(s):  
Maternal Serum ◽  
Dna Testing ◽  
Cell Free Dna ◽  
Free Dna

First-Trimester Contingent Screening for Trisomy 21 by Fetal Nuchal Translucency and Maternal Serum Biomarkers and Maternal Blood Cell-Free DNA Testing

2018 ◽  
Vol 5 (3) ◽  
pp. 139-143
Author(s):  
Sarang Younesi ◽  
Shahram Savad ◽  
Soudeh Ghafouri-Fard ◽  
Mohammad Mahdi Taheri-Amin ◽  
Pourandokht Saadati ◽  
...  
Keyword(s):  
Blood Cell ◽  
Trisomy 21 ◽  
First Trimester ◽  
Nuchal Translucency ◽  
Maternal Blood ◽  
Maternal Serum ◽  
Serum Biomarkers ◽  
Dna Testing ◽  
Cell Free Dna ◽  
Free Dna

Prenatal Screening and Diagnosis

2018 ◽  
Author(s):  
Barbara O’Brien ◽  
Emily Willner
Keyword(s):  
Diagnostic Testing ◽  
Chorionic Villus ◽  
Clinical History ◽  
Maternal Serum ◽  
Specific Gene ◽  
Chorionic Villus Sampling ◽  
Genetic Syndromes ◽  
Cell Free Dna ◽  
Free Dna ◽  
Ultrasound Evaluation

Prenatal genetic testing offers patients and providers the opportunity to screen for aneuploidy, genetic syndromes, and congenital malformations during pregnancy. Screening options include taking a clinical history, evaluation of maternal serum markers or noninvasive cell-free DNA, and ultrasound evaluation during the first and second trimesters. Invasive diagnostic testing such as amniocentesis or chorionic villus sampling allows for further investigation of positive screening results and a directed test to identify aneuploidy as well as specific gene mutations and gain, loss, or rearrangement of genetic information. Laboratory methods for testing fetal samples differ by types of genetic abnormalities that can be detected and turnaround time for results; these methods include karyotype, fluorescence in situ hybridization, and microarray.   This review contains 5 figures, 5 tables and 43 references Key words: amniocentesis, aneuploidy, cell-free DNA, chorionic villus sampling, karyotype, microarray, prenatal genetic screening, ultrasonography  

Prenatal Screening

2018 ◽  
Author(s):  
Amber Mathiesen ◽  
Kali Roy
Keyword(s):  
Test Performance ◽  
Predictive Value ◽  
Prenatal Screening ◽  
Maternal Serum ◽  
Dna Testing ◽  
Maternal Serum Screening ◽  
Cell Free Dna ◽  
Free Dna ◽  
Serum Screening

This chapter provides information about a genetic counselor’s role in prenatal screening, including discussing and offering options to a patient, interpreting and providing results, or managing referrals based on abnormal results. It discusses how a screen is evaluated using sensitivity, specificity, positive predictive value, negative predictive value, and personal utility. It provides a detailed description of both maternal serum screening and cell-free DNA testing. The maternal serum screening discussion includes information on multiples of median, calculating risk, timing, pattern association, limitations, and follow-up. The review of cell-free DNA testing includes fetal fraction, methodology, test performance, limitations and considerations for testing, and follow-up. This chapter also provides a list of additional resources to use for cell-free DNA testing.

Prenatal Screening and Diagnosis

2018 ◽  
Author(s):  
Barbara O’Brien ◽  
Emily Willner
Keyword(s):  
Diagnostic Testing ◽  
Chorionic Villus ◽  
Clinical History ◽  
Maternal Serum ◽  
Specific Gene ◽  
Chorionic Villus Sampling ◽  
Genetic Syndromes ◽  
Cell Free Dna ◽  
Free Dna ◽  
Ultrasound Evaluation

Prenatal genetic testing offers patients and providers the opportunity to screen for aneuploidy, genetic syndromes, and congenital malformations during pregnancy. Screening options include taking a clinical history, evaluation of maternal serum markers or noninvasive cell-free DNA, and ultrasound evaluation during the first and second trimesters. Invasive diagnostic testing such as amniocentesis or chorionic villus sampling allows for further investigation of positive screening results and a directed test to identify aneuploidy as well as specific gene mutations and gain, loss, or rearrangement of genetic information. Laboratory methods for testing fetal samples differ by types of genetic abnormalities that can be detected and turnaround time for results; these methods include karyotype, fluorescence in situ hybridization, and microarray.   This review contains 5 figures, 5 tables and 43 references Key words: amniocentesis, aneuploidy, cell-free DNA, chorionic villus sampling, karyotype, microarray, prenatal genetic screening, ultrasonography  

High levels of fetal cell-free DNA in maternal serum: A risk factor for spontaneous preterm delivery

2005 ◽  
Vol 193 (2) ◽  
pp. 421-425 ◽  
Author(s):  
Antonio Farina ◽  
Erik S. LeShane ◽  
Roberto Romero ◽  
Ricardo Gomez ◽  
Tinnakorn Chaiworapongsa ◽  
...  
Keyword(s):  
Risk Factor ◽  
Preterm Delivery ◽  
Maternal Serum ◽  
Fetal Cell ◽  
Cell Free Dna ◽  
Spontaneous Preterm Delivery ◽  
Free Dna

scholarly journals Measuring maternal serum screening markers for Down’s syndrome in plasma collected for cell-free DNA testing

2016 ◽  
Vol 24 (3) ◽  
pp. 113-119 ◽  
Author(s):  
Geralyn M Lambert-Messerlian ◽  
Elizabeth E Eklund ◽  
Louis M Neveux ◽  
Glenn E Palomaki
Keyword(s):  
Down's Syndrome ◽  
Down’S Syndrome ◽  
Maternal Serum ◽  
Dna Testing ◽  
Maternal Serum Screening ◽  
Cell Free Dna ◽  
Free Dna ◽  
Serum Screening
Sign in / Sign up

Export Citation Format

Share Document